Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Non-Controlling Interests (2016 - 2018)

Coherus Oncology's Income from Non-Controlling Interests history spans 5 years, with the latest figure at -$18000.0 for Q3 2018.

  • For Q3 2018, Income from Non-Controlling Interests fell 350.0% year-over-year to -$18000.0; the TTM value through Jun 2019 reached -$18000.0, up 68.97%, while the annual FY2018 figure was -$70000.0, 39.66% up from the prior year.
  • Income from Non-Controlling Interests for Q3 2018 was -$18000.0 at Coherus Oncology, up from -$47000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $111000.0 in Q4 2014 and bottomed at -$224000.0 in Q2 2015.
  • The 5-year median for Income from Non-Controlling Interests is -$56500.0 (2017), against an average of -$75500.0.
  • The largest annual shift saw Income from Non-Controlling Interests soared 95.79% in 2017 before it plummeted 350.0% in 2018.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $111000.0 in 2014, then plummeted by 270.27% to -$189000.0 in 2015, then skyrocketed by 87.83% to -$23000.0 in 2016, then skyrocketed by 91.3% to -$2000.0 in 2017, then plummeted by 800.0% to -$18000.0 in 2018.
  • Per Business Quant, the three most recent readings for CHRS's Income from Non-Controlling Interests are -$18000.0 (Q3 2018), -$47000.0 (Q2 2018), and -$5000.0 (Q1 2018).